Amgen Inc. $AMGN Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 71.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,137,313 shares of the medical research company’s stock after acquiring an additional 475,799 shares during the quarter. Victory Capital Management Inc.’s holdings in Amgen were worth $372,254,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in AMGN. Norges Bank acquired a new stake in shares of Amgen during the fourth quarter worth approximately $2,164,162,000. Capital World Investors grew its position in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares in the last quarter. Finally, National Bank of Canada FI grew its position in shares of Amgen by 237.7% during the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after buying an additional 863,216 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Amgen Stock Performance

AMGN stock opened at $355.20 on Friday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $191.70 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 3.55 and a beta of 0.42. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The stock’s fifty day moving average is $340.97 and its two-hundred day moving average is $345.72.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on AMGN. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. UBS Group lifted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Royal Bank Of Canada lifted their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, Jefferies Financial Group initiated coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $354.12.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.